Join to View Full Profile
1515 Holcombe BlvdMD Anderson Cancer Ctr, Unit 428Houston, TX 77030
Phone+1 713-792-6161
Dr. Keating is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
University of Melbourne Faculty of MedicineClass of 1966
Certifications & Licensure
TX State Medical License 1975 - 2025
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach Start of enrollment: 2001 Dec 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Publications & Presentations
PubMed
- CLL cell-derived exosomes alter the immune and hematopoietic systems.Ivo Veletic, David M Harris, Uri Rozovski, Maria Teresa S Bertilaccio, George A Calin
Leukemia. 2025-04-04 - The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers.Recep Bayraktar, Yitao Tang, Mihnea P Dragomir, Cristina Ivan, Xinxin Peng
Science Advances. 2025-02-21 - A pilot study of lower doses of ibrutinib: patient body weight does not correlate with plasma ibrutinib levels during therapy.Lisa S Chen, Prithviraj Bose, Wei Qiao, Yongying Jiang, Qi Wu
Leukemia & Lymphoma. 2025-02-08
Journal Articles
- Trisomy 12 Chronic Lymphocytic Leukemia Expresses a Unique Set of Activated and Targetable PathwaysMichael J Keating, Lynne V Abruzzo, Haematologica
- A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic LeukemiaNitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Press Mentions
What Options Are Available for CLL Patients Who Relapse After Ibrutinib?February 21st, 2019
Grant Support
- Clinical Research CoreNational Cancer Institute2006–2010
- Clinical ConsortiumNational Cancer Institute2000–2002
- Clinical ConsosrtiumNational Cancer Institute1999
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
